Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2021/05/033533
CTRI/2021/05/033533
Not yet recruiting
未知

Pharmacometrics evaluation and antimicrobial efficacy of standard meropenem dosing in gram negative sepsis: A longitudinal, sigle center study

Manipal Center for Infectious Diseases MAC ID0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: A415- Sepsis due to other Gram-negativeorganisms

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: A415- Sepsis due to other Gram-negativeorganisms
Sponsor
Manipal Center for Infectious Diseases MAC ID
Status
Not yet recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Manipal Center for Infectious Diseases MAC ID

Eligibility Criteria

Inclusion Criteria

  • •1\.Patients diagnosed with sepsis or septic shock: suspicion of infection and microbiological sampling undertaken, received meropenem, vasopressor therapy needed to elevate mean arterial pressure \>\=65 mmHg and lactate \>2mmol/L (18mg/dL) despite adequate fluid resuscitation
  • •2\. Confirmed infection by Gram negative organism (Klebsiella pneumoniae, Escherichia coli and/or Pseudomonas aeruginosa)

Exclusion Criteria

  • •1\.Pregnant or lactating women
  • •2\.Documented hypersensitivity to carbapenems
  • •3\.Patients with an anticipated hospitalization of \<\=2 days
  • •4\.Patients with chronic kidney disease (CKD)
  • •5\.Extra\-corporeal circulation in the month preceding inclusion in the case of cardiac surgery
  • •6\.Blood transfusion \>4 units in past week
  • •7\.Patient with restricted liberty or under legal protection
  • •8\.Inability to consent the patient or next of kin
  • •9\.Second admission to ICU or previous enrolment in study (within same hospital admission)
  • •10\.Transfer from other hospital ICUs (if stay \>24 hrs)

Outcomes

Primary Outcomes

Not specified

Similar Trials

Active, not recruiting
Phase 1
Clinical Study Toothpaste base Rosemary on Plaque and Saliva Bacterium
RBR-9f3ctbFPE-Universidade Federal de Pernambuco
Completed
Phase 2
A novel drug to treat gum diseases.
CTRI/2019/05/019477Dayananda Sagar College of Dental Sciences26
Completed
Phase 2
A clinical study to compare and evaluate the anti bacterial effect of 5% herbal mouthwash and 0.2% chlorhexidine mouthwash in high decay prone individuals.
CTRI/2020/04/024840SRM Dental College30
Not yet recruiting
Phase 3
A Comparison of the Property Against the Micro-organisms in the Root Canal, between Octenidine Dihydrochloride Chlorhexidine and Sodium Hypochlorite as Irrigating solutions: A Randomized Controlled Trial
CTRI/2024/06/068447Guru Nanak Institute of Dental Sciences and Research
Not yet recruiting
Phase 3
Antimicrobial effect of Licorice and Triphala lollipops on Streptococcus mutans count in children.
CTRI/2022/02/039974AKV ENTERPRISES